The trading price of Xeris Biopharma Holdings Inc (NASDAQ:XERS) remained unchanged on Tuesday, April 23, closing at $1.78.
In examining the 52-week price action we see that the stock hit a 52-week high of $3.26 and a 52-week low of $1.46. Over the past month, the stock has lost -15.24% in value.
Xeris Biopharma Holdings Inc, whose market valuation is $250.00 million at the time of this writing. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -0.12 per share this quarter, however they have predicted annual earnings per share of -0.38 for current year and -0.22 for next year.
Analysts have forecast the company to bring in revenue of 41.81M for the current quarter, with the likely lows of 37.97M and highs of 44M. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 184.43M.
On the technical side, indicators suggest XERS has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 50% Sell.
A quick review shows that XERS’s price is currently -9.83% off the SMA20 and -26.22% off the SMA50. The RSI metric on the 14-day chart is currently showing 29.83, and weekly volatility stands at 5.97%. When measured over the past 30 days, the indicator reaches 5.33%. Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s beta value is currently sitting at 1.66, while the Average True Range indicator is currently displaying 0.12.
To see how Xeris Biopharma Holdings Inc stock has been performing in comparison to its peers in the industry, here are the numbers: XERS stock’s performance was 0.00% in the latest trading, and -22.94% in the past year.
An evaluation of the daily trading volume of Xeris Biopharma Holdings Inc (NASDAQ:XERS) indicates that the 3-month average is 1.91 million.
Currently, records show that 138.13 million of the company’s shares remain outstanding. The insiders hold 10.60% of outstanding shares, whereas institutions hold 41.01%. However, since the stock’s price has seen -24.26% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
